Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

First effective treatment for chemotherapy-induced peripheral neuropathy

2012 ASCO Annual Meeting

Published: 4 Jun 2012

Views: 4561

Rating:

Save

Dr Ellen Lavoie Smith - University of Michigan, Ann Arbor, USA

At a press conference during the ASCO 2012 Annual Meeting in Chicage, June 1st - June 4th, Dr Ellen Lavoie Smith presented findings from a phase III study where it was discovered that duloxetine is effective in treating painful chemotherapy-induced peripheral neuropathy.

This finding will likely change oncology practice and offers an important new quality of life solution for patients.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

Low-dose olanzapine after highly emetogenic chemotherapy can be the new...

Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours ( Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Real-world behavioural restrictional practices of cancer patients

Dr Daniel Vorobiof - Belong.Life, New York, USA

Real-world behavioural restrictional practices of cancer patients ( Dr Daniel Vorobiof - Belong.Life, New York, USA )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

Assessment of QoL results and correlation with survival outcomes in phase III...

Dr Alberto Servetto - University of Naples Federico II, Naples, Italy

Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC ( Dr Alberto Servetto - University of Naples Federico II, Naples, Italy )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer